Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Dosage Regimen: Individualization

Dosage Regimen: Individualization

Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...

Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration

Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration

Drug elimination from the body primarily occurs through metabolic and excretion pathways. Hepatic metabolism transforms lipophilic drugs into hydrophilic forms for excretion, typically via enzymatic processes classified as phase I (modification) and phase II (conjugation). Renal excretion eliminates drugs and metabolites through filtration and secretion in the kidneys. Impairment in liver or kidney function can hinder these processes, delaying drug clearance and extending the drug’s half-life.

Pharmacokinetics in Pediatric Patients: Drug Excretion

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

Nonlinear Pharmacokinetics: Causes of Nonlinearity

Nonlinear Pharmacokinetics: Causes of Nonlinearity

Nonlinearity in drug pharmacokinetics is caused by various factors influencing how a drug is absorbed, distributed, metabolized, and excreted. Understanding these nonlinear processes is crucial for predicting drug behavior in the body and optimizing drug dosing regimens.
Nonlinear drug absorption can occur when the process is rate-limited by solubility, carrier-mediated transport systems, or saturation of the presystemic gut wall or hepatic metabolism. For instance, high doses of riboflavin...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Suboptimal exposure to fluconazole in critically ill patients: Pharmacokinetic analysis and determinants.

Infectious diseases now·2022

Same author

Antibiotic therapy for infectious hemodialysed patients in Bamako: Pharmacokinetic analyses and first improvement suggestions.

Annales pharmaceutiques francaises·2022

Same author

Estimating renal function when adjusting the dosage of antibiotics: Facts and fables.

Infectious diseases now·2021

Same author

Drug-related problems among older patients: Analysis of 8 years of pharmacist's interventions.

Annales pharmaceutiques francaises·2021

Same author

Tolerance and microbiological efficacy of cefepime or piperacillin/tazobactam in combination with vancomycin as empirical antimicrobial therapy of prosthetic joint infection: a propensity-matched cohort study.

The Journal of antimicrobial chemotherapy·2020

Same author

[Reevaluating the shelf life of sterilized packaged items via a risk-analysis study].

Annales pharmaceutiques francaises·2020

Search research articles

Related Experiment Video

Updated: Jun 24, 2026

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

[Interindividual pharmacokinetic variability in long-term antibiotherapy].

L Bourguignon¹, S Goutelle, J Burdin de Saint Martin

¹Université Lyon-1, UMR CNRS 5558, biométrie et biologie évolutive, bâtiment G.-Mendel, 43, boulevard du 11-Novembre-1918, 69622 Villeurbanne cedex, France. laurent.bourguignon@chu-lyon.fr

Medecine Et Maladies Infectieuses

|April 7, 2009

Summary

This study assessed pharmacokinetic variability in a patient receiving long-term amikacin therapy. High intraindividual variability was observed, highlighting the need for periodic patient re-evaluation during treatment.

More Related Videos

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

Population and Single-Cell Analysis of Antibiotic Persistence in Escherichia coli

Population and Single-Cell Analysis of Antibiotic Persistence in Escherichia coli

Published on: March 24, 2023

Related Experiment Videos

Last Updated: Jun 24, 2026

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

Population and Single-Cell Analysis of Antibiotic Persistence in Escherichia coli

Population and Single-Cell Analysis of Antibiotic Persistence in Escherichia coli

Published on: March 24, 2023

Area of Science:

Pharmacokinetics
Drug Metabolism and Transport
Clinical Pharmacology

Background:

Long-term amikacin therapy requires careful monitoring due to potential toxicity.
Understanding pharmacokinetic variability is crucial for optimizing drug efficacy and safety.

Observation:

A 92-year-old female patient with renal failure received amikacin for 52 days.
Pharmacokinetic parameters were assessed 12 times to quantify intraindividual variability.
Variability was compared against established interindividual data.

Findings:

Intraindividual volume and clearance variability were significantly lower than interindividual variability.
Half-life intraindividual variability was comparable to interindividual variability (24.5% vs. 32%).

Implications:

High pharmacokinetic variability has significant clinical implications for treatment effectiveness.
Periodic reassessment of patient status is essential to manage intraindividual pharmacokinetic variability.
This case underscores the importance of individualized dosing strategies in long-term amikacin treatment.